XOMA Corp
NASDAQ:XOMA

Watchlist Manager
XOMA Corp Logo
XOMA Corp
NASDAQ:XOMA
Watchlist
Price: 30.2 USD 0.43% Market Closed
Market Cap: 355.8m USD
Have any thoughts about
XOMA Corp?
Write Note

XOMA Corp
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

XOMA Corp
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
XOMA Corp
NASDAQ:XOMA
Short-Term Investments
$785k
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Abbvie Inc
NYSE:ABBV
Short-Term Investments
$28m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Short-Term Investments
$1.3B
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Short-Term Investments
$7.8B
CAGR 3-Years
49%
CAGR 5-Years
39%
CAGR 10-Years
35%
No Stocks Found

XOMA Corp
Glance View

Market Cap
355m USD
Industry
Biotechnology

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

XOMA Intrinsic Value
34.96 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is XOMA Corp's Short-Term Investments?
Short-Term Investments
785k USD

Based on the financial report for Sep 30, 2024, XOMA Corp's Short-Term Investments amounts to 785k USD.

What is XOMA Corp's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
-17%

Over the last year, the Short-Term Investments growth was 293%. The average annual Short-Term Investments growth rates for XOMA Corp have been -13% over the past three years , and -17% over the past ten years .

Back to Top